Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Buy the dip in this major pharma stock - Citi
May 6, 2024 9:30 AM EDTCiti analysts said in a note Monday that they believe history shows the dip in one major pharmaceutical company's shares should be bought.
The investment bank said Novo Nordisk (NYSE: NVO) remains Buy-rated, while the firm also maintained a Dkr975.00 price target on the stock.... More
Novo Nordisk, Eli Lilly drop on Amgen competition concerns
May 3, 2024 7:15 AM EDT(Updated - May 3, 2024 7:48 AM EDT)
Shares of Novo Nordisk (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY) are down premarket Friday as competition in the GLP-1 market. Amgen (NASDAQ: AMGN) disclosed that it looked at AMG133's unblinded phase 2 interim trial and came away confident in 133's differentiated... More
Amgen (AMGN) PT Raised to $307 at UBS
May 3, 2024 7:06 AM EDTUBS analyst Colin Bristow raised the price target on Amgen (NASDAQ: AMGN) to $307.00 (from $284.00) while maintaining a Neutral rating.
The analyst comments "The much anticipated MariTide interim completed (earlier than we expected) with mgmt providing positive qualitative commentary, as we had expected. At face... More
